Printer Friendly

WYETH-AYERST'S ORUVAIL RECEIVES FDA MARKET CLEARANCE

 PHILADELPHIA, Sept. 27 /PRNewswire/ -- Wyeth-Ayerst Laboratories, Division of American Home Products Corporation (NYSE: AHP), today announced market clearance for ORUVAIL(R)(ketoprofen) 200 mg extended- release capsules, the first nonsteroidal anti-inflammatory drug in an extended-release, once-a-day, pH-dependent dosage form.
 New ORUVAIL is indicated for the management of the signs and symptoms of osteoarthritis and rheumatoid arthritis, conditions that affect 15.8 million and 2.1 million Americans respectively. It will be available in the United States in fall 1993. ORUVAIL has been marketed in the United Kingdom for more than 10 years and is currently available in 40 other countries.
 Wyeth-Ayerst is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and infant nutritionals. American Home Products Corporation is one of the world leaders in prescription drugs, packaged medicines, medical supplies, instrumentation and foods.
 -0- 9/27/93
 /CONTACT: Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823/
 (AHP)


CO: Wyeth-Ayerst Laboratories; American Home Products Corporation ST: Pennsylvania IN: MTC SU:

LG -- NY064 -- 5961 09/27/93 13:25 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 27, 1993
Words:185
Previous Article:INTERNATIONAL SKYLINE GOLD ENTERS JOINT VENTURE WITH AUSPEX GOLD LTD.
Next Article:GTE FLORIDA AND GTE CALIFORNIA TO REDEEM DEBT ISSUES LISTED ON THE AMERICAN AND PACIFIC STOCK EXCHANGES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters